Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); 2012 Catalyst Highlights
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target of $43.00.
Analyst, George Farmer, said, "In our view, expected H1/12 read-out from the Phase III MISSION trial of Nexavar in non-small cell lung cancer (NSCLC) is the most significant near-term catalyst for ONXX shares. We see limited upside even on positive trial data, given: (1) subgroup confinement to the 70% of NSCLC patients with non-squamous disease, (2) side effects limiting potential treatment duration, and (3) few real-world patients reaching targeted 3rd/4th line of therapy. We await MISSION data before modeling Nexavar sales in NSCLC."
"Maintaining our rating on ONXX shares, we caution against over-enthusiasm for select near-term 2012 catalysts related to Nexavar and regorafenib."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $42.09 yesterday.
Analyst, George Farmer, said, "In our view, expected H1/12 read-out from the Phase III MISSION trial of Nexavar in non-small cell lung cancer (NSCLC) is the most significant near-term catalyst for ONXX shares. We see limited upside even on positive trial data, given: (1) subgroup confinement to the 70% of NSCLC patients with non-squamous disease, (2) side effects limiting potential treatment duration, and (3) few real-world patients reaching targeted 3rd/4th line of therapy. We await MISSION data before modeling Nexavar sales in NSCLC."
"Maintaining our rating on ONXX shares, we caution against over-enthusiasm for select near-term 2012 catalysts related to Nexavar and regorafenib."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $42.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
